Show simple item record

dc.contributor.authorSchroeder, B.A.
dc.contributor.authorLafranzo, N.A.
dc.contributor.authorLafleur, B.J.
dc.contributor.authorGittelman, R.M.
dc.contributor.authorVignali, M.
dc.contributor.authorZhang, S.
dc.contributor.authorFlanagan, K.C.
dc.contributor.authorRytlewski, J.
dc.contributor.authorRiolobos, L.
dc.contributor.authorSchulte, B.C.
dc.contributor.authorKim, T.S.
dc.contributor.authorChen, E.
dc.contributor.authorSmythe, K.S.
dc.contributor.authorWagner, M.J.
dc.contributor.authorMantilla, J.G.
dc.contributor.authorCampbell, J.S.
dc.contributor.authorPierce, R.H.
dc.contributor.authorJones, R.L.
dc.contributor.authorCranmer, L.D.
dc.contributor.authorPollack, S.M.
dc.date.accessioned2021-09-24T20:58:57Z
dc.date.available2021-09-24T20:58:57Z
dc.date.issued2021
dc.identifier.citationSchroeder, B. A., Lafranzo, N. A., Lafleur, B. J., Gittelman, R. M., Vignali, M., Zhang, S., Flanagan, K. C., Rytlewski, J., Riolobos, L., Schulte, B. C., Kim, T. S., Chen, E., Smythe, K. S., Wagner, M. J., Mantilla, J. G., Campbell, J. S., Pierce, R. H., Jones, R. L., Cranmer, L. D., & Pollack, S. M. (2021). CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. Journal for ImmunoTherapy of Cancer, 9(8).
dc.identifier.issn2051-1426
dc.identifier.doi10.1136/jitc-2021-002812
dc.identifier.urihttp://hdl.handle.net/10150/661904
dc.description.abstractBackground Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, little is known about the immune microenvironment in relation to patient prognosis. Methods We performed a retrospective study of 61 patients with DDLPS. We completed deep sequencing of the T-cell receptor (TCR) β-chain and RNA sequencing for predictive modeling, evaluating both immune markers and tumor escape genes. Hierarchical clustering and recursive partitioning were employed to elucidate relationships of cellular infiltrates within the tumor microenvironment, while an immune score for single markers was created as a predictive tool. Results Although many DDLPS samples had low TCR clonality, high TCR clonality combined with low T-cell fraction predicted lower 3-year overall survival (p=0.05). Higher levels of CD14+ monocytes (p=0.02) inversely correlated with 3-year recurrence-free survival (RFS), while CD4+ T-cell infiltration (p=0.05) was associated with a higher RFS. Genes associated with longer RFS included PD-1 (p=0.003), ICOS (p=0.006), BTLA (p=0.033), and CTLA4 (p=0.02). In a composite immune score, CD4+ T cells had the strongest positive predictive value, while CD14+ monocytes and M2 macrophages had the strongest negative predictive values. Conclusions Immune cell infiltration predicts clinical outcome in DDLPS, with CD4+ cells associated with better outcomes; CD14+ cells and M2 macrophages are associated with worse outcomes. Future checkpoint inhibitor studies in DDLPS should incorporate immunosequencing and gene expression profiling techniques that can generate immune landscape profiles. © 2021 BMJ Publishing Group. All rights reserved.
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.rightsCopyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC.
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCD4-positive T-lymphocytes
dc.subjectimmunity
dc.subjectmacrophages
dc.subjectsarcoma
dc.subjecttumor microenvironment
dc.titleCD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes
dc.typeArticle
dc.typetext
dc.contributor.departmentBIO5 Institute, University of Arizona
dc.identifier.journalJournal for ImmunoTherapy of Cancer
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleJournal for ImmunoTherapy of Cancer
refterms.dateFOA2021-09-24T20:58:57Z


Files in this item

Thumbnail
Name:
e002812.full.pdf
Size:
5.096Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

Copyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC.
Except where otherwise noted, this item's license is described as Copyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC.